These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23931109)

  • 1. Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells.
    Marzenell P; Hagen H; Sellner L; Zenz T; Grinyte R; Pavlov V; Daum S; Mokhir A
    J Med Chem; 2013 Sep; 56(17):6935-44. PubMed ID: 23931109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoferrocene-based prodrugs activated by reactive oxygen species.
    Hagen H; Marzenell P; Jentzsch E; Wenz F; Veldwijk MR; Mokhir A
    J Med Chem; 2012 Jan; 55(2):924-34. PubMed ID: 22185340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of aminoferrocene-based prodrugs against prostate cancer.
    Schikora M; Reznikov A; Chaykovskaya L; Sachinska O; Polyakova L; Mokhir A
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3447-50. PubMed ID: 26206503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the structure of aminoferrocene-based anticancer prodrugs to prevent their aggregation in aqueous solution.
    Daum S; Babiy S; Konovalova H; Hofer W; Shtemenko A; Shtemenko N; Janko C; Alexiou C; Mokhir A
    J Inorg Biochem; 2018 Jan; 178():9-17. PubMed ID: 29028541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Azidobenzyl ferrocenylcarbamate as an anticancer prodrug activated under reductive conditions.
    Kinski E; Marzenell P; Hofer W; Hagen H; Raskatov JA; Knaup KX; Zolnhofer EM; Meyer K; Mokhir A
    J Inorg Biochem; 2016 Jul; 160():218-24. PubMed ID: 26970945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox-dependent cytotoxicity of ferrocene derivatives and ROS-activated prodrugs based on ferrocenyliminoboronates.
    Věžník J; Konhefr M; Fohlerová Z; Lacina K
    J Inorg Biochem; 2021 Nov; 224():111561. PubMed ID: 34385077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with
    Daum S; Toms J; Reshetnikov V; Özkan HG; Hampel F; Maschauer S; Hakimioun A; Beierlein F; Sellner L; Schmitt M; Prante O; Mokhir A
    Bioconjug Chem; 2019 Apr; 30(4):1077-1086. PubMed ID: 30768258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.
    Levovich I; Nudelman A; Berkovitch G; Swift LP; Cutts SM; Phillips DR; Rephaeli A
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):471-82. PubMed ID: 18030472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS-Responsive N-Alkylaminoferrocenes for Cancer-Cell-Specific Targeting of Mitochondria.
    Reshetnikov V; Daum S; Janko C; Karawacka W; Tietze R; Alexiou C; Paryzhak S; Dumych T; Bilyy R; Tripal P; Schmid B; Palmisano R; Mokhir A
    Angew Chem Int Ed Engl; 2018 Sep; 57(37):11943-11946. PubMed ID: 30035345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Cytotoxicity through Photorelease of Aminoferrocene.
    Leonidova A; Anstaett P; Pierroz V; Mari C; Spingler B; Ferrari S; Gasser G
    Inorg Chem; 2015 Oct; 54(20):9740-8. PubMed ID: 26440628
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Reshetnikov V; Özkan HG; Daum S; Janko C; Alexiou C; Sauer C; Heinrich MR; Mokhir A
    Molecules; 2020 May; 25(11):. PubMed ID: 32486084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.
    Daum S; Reshetnikov MSV; Sisa M; Dumych T; Lootsik MD; Bilyy R; Bila E; Janko C; Alexiou C; Herrmann M; Sellner L; Mokhir A
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15545-15549. PubMed ID: 28994179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation of twenty-eight ferrocenyl tetrasubstituted olefins: cancer cell growth inhibition, ROS production and hemolytic activity.
    de Oliveira AC; Hillard EA; Pigeon P; Rocha DD; Rodrigues FA; Montenegro RC; Costa-Lotufo LV; Goulart MO; Jaouen G
    Eur J Med Chem; 2011 Sep; 46(9):3778-87. PubMed ID: 21696865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
    Peng X; Gandhi V
    Ther Deliv; 2012 Jul; 3(7):823-33. PubMed ID: 22900465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxicity of electrophilic iron(II)-clathrochelates in human promyelocytic leukemia cell line.
    Blechinger J; Varzackii OA; Kovalska V; Zelinskii GE; Voloshin YZ; Kinski E; Mokhir A
    Bioorg Med Chem Lett; 2016 Jan; 26(2):626-629. PubMed ID: 26631314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, cytotoxicity, and COMPARE analysis of ferrocene and [3]ferrocenophane tetrasubstituted olefin derivatives against human cancer cells.
    Görmen M; Pigeon P; Top S; Hillard EA; Huché M; Hartinger CG; de Montigny F; Plamont MA; Vessières A; Jaouen G
    ChemMedChem; 2010 Dec; 5(12):2039-50. PubMed ID: 20949584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced anticancer activity of glutamate prodrugs of all-trans retinoic acid.
    Cui C; Zhang Y; Wang L; Liu H; Cui G
    J Pharm Pharmacol; 2009 Oct; 61(10):1353-8. PubMed ID: 19814868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters.
    Lin YS; Tungpradit R; Sinchaikul S; An FM; Liu DZ; Phutrakul S; Chen ST
    J Med Chem; 2008 Dec; 51(23):7428-41. PubMed ID: 19053781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.